Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
The market is a bit jittery right now thanks to a confluence of factors, including a weaker-than-anticipated U.S. jobs report, international geopolitical issues, and foreign currency disruptions -- all of which led to a sell-off on Aug. 5. It's reasonable for investors to be a bit nervous about committing more of their capital given the volatility and ongoing uncertainty.
Nonetheless, I predict that loading up on a basket of biopharma stocks during this unsteadiness will prove to be a profitable decision in the long run. Here's why.
To start, let's examine the mid-sell-off performance of a few popular biotech and pharma stocks. Recursion Pharmaceuticals (NASDAQ: RXRX), Eli Lilly (NYSE: LLY), Viking Therapeutics (NASDAQ: VKTX), and (NYSE: PFE) are all depicted in the chart below:
Source Fool.com
Pfizer Inc. Aktie
Die Community bevorzugt klar Pfizer Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Das Community-Kursziel von 41 € für Pfizer Inc. deutet auf eine deutliche Steigerung um mehr als 50% gegenüber dem aktuellen Kurs von 26.38 € hin.
